These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25326842)

  • 1. [Safety and tolerability of GLP-1 receptor agonists].
    Soldevila B; Puig-Domingo M
    Med Clin (Barc); 2014; 143 Suppl 2():35-40. PubMed ID: 25326842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Safety and tolerability of GLP-1 receptor agonists].
    Soldevila B; Puig-Domingo M
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():35-40. PubMed ID: 25437464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An updated review on cancer risk associated with incretin mimetics and enhancers.
    Tseng CH; Lee KY; Tseng FH
    J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The safety and tolerability of GLP-1 receptor agonists in the treatment of type-2 diabetes.
    Russell-Jones D
    Int J Clin Pract; 2010 Sep; 64(10):1402-14. PubMed ID: 20716148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
    Aroda VR; Ratner R
    Diabetes Metab Res Rev; 2011 Sep; 27(6):528-42. PubMed ID: 21484979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse Effects of GLP-1 Receptor Agonists.
    Filippatos TD; Panagiotopoulou TV; Elisaf MS
    Rev Diabet Stud; 2014; 11(3-4):202-30. PubMed ID: 26177483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.
    Peng H; Want LL; Aroda VR
    Curr Diab Rep; 2016 May; 16(5):44. PubMed ID: 27037706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incretin mimetics and acute pancreatitis: enemy or innocent bystander?
    Pratley R; Saeed ZI; Casu A
    Curr Opin Gastroenterol; 2024 Sep; 40(5):404-412. PubMed ID: 38967917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
    Monami M; Nreu B; Scatena A; Cresci B; Andreozzi F; Sesti G; Mannucci E
    Diabetes Obes Metab; 2017 Sep; 19(9):1233-1241. PubMed ID: 28244632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of glucagon-like peptide-1 receptor agonists: unresolved and emerging issues.
    Raccah D
    Expert Opin Drug Saf; 2017 Feb; 16(2):227-236. PubMed ID: 27924636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLP-1R agonist therapy for diabetes: benefits and potential risks.
    Samson SL; Garber A
    Curr Opin Endocrinol Diabetes Obes; 2013 Apr; 20(2):87-97. PubMed ID: 23403741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.
    Liu Y; Tian Q; Yang J; Wang H; Hong T
    Diabetes Metab Res Rev; 2018 Nov; 34(8):e3061. PubMed ID: 30109766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials.
    Bettge K; Kahle M; Abd El Aziz MS; Meier JJ; Nauck MA
    Diabetes Obes Metab; 2017 Mar; 19(3):336-347. PubMed ID: 27860132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
    Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
    Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.
    Chalmer T; Almdal TP; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2015 Jan; 14(1):171-80. PubMed ID: 25363438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].
    Jermendy G
    Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential harms of type 2 diabetes drugs have been ignored, finds BMJ investigation.
    Kmietowicz Z
    BMJ; 2013 Jun; 346():f3782. PubMed ID: 23757752
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.